TitleAssistant Professor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Bertucci F, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz C. Correction: Maternal Embryonic Leucine Zipper Kinase Is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun. 2024 Jan 29; 4(1):236. PMID: 38282551; PMCID: PMC10823323.
    2. Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz C. Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Res Commun. 2023 06; 3(6):1078-1092. PMID: 37377604; PMCID: PMC10281291.
      Citations:    Translation:HumansAnimalsCells
    3. Park J, Tacam MJ, Chauhan G, Cohen EN, Gagliardi M, Iles LR, Ueno NT, Battula VL, Sohn YK, Wang X, Kim HS, Krishnamurthy S, Fowlkes NW, Green MM, Bartholomeusz GA, Tripathy D, Reuben JM, Bartholomeusz C. Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Res Treat. 2021 Sep; 189(2):333-345. PMID: 34241740; PMCID: PMC8357760.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    4. Xie X, Lee J, Liu H, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, Ueno NT. Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. Mol Cancer Ther. 2021 02; 20(2):296-306. PMID: 33323457; PMCID: PMC8747014.
      Citations: 3     Fields:    Translation:HumansAnimals
    5. Gagliardi M, Pitner MK, Park J, Xie X, Saso H, Larson RA, Sammons RM, Chen H, Wei C, Masuda H, Chauhan G, Kondo K, Tripathy D, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz C. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Sci Rep. 2020 05 22; 10(1):8537. PMID: 32444778; PMCID: PMC7244517.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    6. Dilruba S, Grondana A, Schiedel AC, Ueno NT, Bartholomeusz C, Cinatl J, McLaughlin KM, Wass MN, Michaelis M, Kalayda GV. Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells. 2020 02 24; 9(2). PMID: 32102425; PMCID: PMC7072772.
      Citations: 5     Fields:    Translation:HumansCells
    7. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jul; 176(1):251. PMID: 30982934.
      Citations:    Fields:    
    8. Sammons RM, Perry NA, Li Y, Cho EJ, Piserchio A, Zamora-Olivares DP, Ghose R, Kaoud TS, Debevec G, Bartholomeusz C, Gurevich VV, Iverson TM, Giulianotti M, Houghten RA, Dalby KN. A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation. ACS Chem Biol. 2019 06 21; 14(6):1183-1194. PMID: 31058487; PMCID: PMC7105935.
      Citations: 5     Fields:    Translation:HumansCells
    9. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351. PMID: 30826934; PMCID: PMC6534477.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    10. Jose J, Tavares CDJ, Ebelt ND, Lodi A, Edupuganti R, Xie X, Devkota AK, Kaoud TS, Van Den Berg CL, Anslyn EV, Tiziani S, Bartholomeusz C, Dalby KN. Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth. ACS Med Chem Lett. 2017 Oct 12; 8(10):1072-1076. PMID: 29057053; PMCID: PMC5641961.
      Citations: 6     
    11. Pitner MK, Taliaferro JM, Dalby KN, Bartholomeusz C. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opin Ther Targets. 2017 09; 21(9):849-859. PMID: 28764577.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    12. Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT. EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget. 2017 Sep 15; 8(40):67904-67917. PMID: 28978083; PMCID: PMC5620223.
      Citations: 17     Fields:    
    13. Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M. IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget. 2017 Jun 06; 8(23):36936-36949. PMID: 28415808; PMCID: PMC5514883.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    14. Edupuganti R, Taliaferro JM, Wang Q, Xie X, Cho EJ, Vidhu F, Ren P, Anslyn EV, Bartholomeusz C, Dalby KN. Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth. Bioorg Med Chem. 2017 05 01; 25(9):2609-2616. PMID: 28351607.
      Citations: 12     Fields:    Translation:HumansCells
    15. Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer. 2015; 6(12):1306-19. PMID: 26640591; PMCID: PMC4643087.
      Citations: 9     
    16. Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther. 2015 Dec; 14(12):2687-99. PMID: 26443806; PMCID: PMC4674309.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    17. Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Mol Cancer Ther. 2015 Dec; 14(12):2773-81. PMID: 26384399; PMCID: PMC4674314.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    18. Boulbes DR, Chauhan GB, Jin Q, Bartholomeusz C, Esteva FJ. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat. 2015 Jun; 151(3):501-13. PMID: 25971596.
      Citations: 28     Fields:    Translation:HumansCells
    19. Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, Esteva FJ. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 2015 Mar; 9(3):586-600. PMID: 25435280; PMCID: PMC4815926.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    20. Xie X, Tang H, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT, Xie X. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 2015 Jan 28; 356(2 Pt B):374-381. PMID: 25304382; PMCID: PMC4571276.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    21. Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014 Jul; 146(2):259-72. PMID: 24916181; PMCID: PMC4119423.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    22. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500. PMID: 24703838; PMCID: PMC4038960.
      Citations: 26     Fields:    Translation:HumansCells
    23. Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN, Ueno NT. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther. 2013 Jun; 12(6):1099-111. PMID: 23543364; PMCID: PMC3681833.
      Citations: 10     Fields:    Translation:HumansCells
    24. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):331-45. PMID: 23073759; PMCID: PMC3832208.
      Citations: 233     Fields:    Translation:Humans
    25. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortob?gyi GN. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist. 2012; 17(6):766-74. PMID: 22584435; PMCID: PMC3380875.
      Citations: 51     Fields:    Translation:Humans
    26. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan; 16(1):121-30. PMID: 22239433.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    27. Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012 Feb; 11(2):360-9. PMID: 22144664; PMCID: PMC3320047.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    28. Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NT. Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. J Cancer. 2011; 2:435-42. PMID: 21850211; PMCID: PMC3157020.
      Citations: 11     
    29. Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist. 2011; 16(7):956-65. PMID: 21712485; PMCID: PMC3228141.
      Citations: 8     Fields:    Translation:HumansCells
    30. Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NT. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep; 122(3):641-7. PMID: 21652059.
      Citations: 12     Fields:    Translation:HumansCells
    31. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol. 2010 Dec; 100(3):449-57. PMID: 20455002.
      Citations: 8     Fields:    Translation:Humans
    32. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res. 2010 Mar 15; 16(6):1802-11. PMID: 20215547.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    33. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res. 2008 Nov 15; 68(22):9302-10. PMID: 19010903; PMCID: PMC2676677.
      Citations: 34     Fields:    Translation:HumansCells
    34. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2008 Jul; 7(7):1846-50. PMID: 18644997; PMCID: PMC2525738.
      Citations: 37     Fields:    Translation:HumansCells
    35. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007 Aug; 6(8):2168-77. PMID: 17671085; PMCID: PMC2603172.
      Citations: 29     Fields:    Translation:HumansCells
    36. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 2007 Jun 15; 67(12):5779-88. PMID: 17575145.
      Citations: 47     Fields:    Translation:HumansCells
    37. Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther. 2007 Jan; 6(1):227-35. PMID: 17218636.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    38. Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res. 2007; 9(4):R41. PMID: 17612393; PMCID: PMC2206712.
      Citations: 3     Fields:    Translation:HumansCells
    39. Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NT. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther. 2006 May; 13(5):451-9. PMID: 16294215.
      Citations: 1     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    40. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene. 2006 Jan 05; 25(1):79-90. PMID: 16170361.
      Citations: 20     Fields:    Translation:HumansCells
    41. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15; 65(18):8406-13. PMID: 16166319.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    42. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33. PMID: 11454891.
      Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
    43. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9. PMID: 10656456.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    44. Gemcitabine overcomes erlotinib resistance in EGFR overexpressing cancer cells through downregulation of Akt. Journal of Cancer. 2:435-442.
    45. Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases. Molecular Cancer Therapeutics. 14:2687-2699.
    46. MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Molecular Cancer Therapeutics. 14:2773-2781.
    47. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. Journal of Cancer. 6:1306-1319.
    BARTHOLOMEUSZ's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (229)
    Co-Authors (33)
    Similar People (60)
    Same Department Expand Description